Short Interest in Surrozen, Inc. (NASDAQ:SRZN) Grows By 43.0%

Surrozen, Inc. (NASDAQ:SRZN) was the target of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 33,900 shares, an increase of 43.0% from the November 15th total of 23,700 shares. Currently, 1.4% of the company’s shares are short sold. Based on an average daily volume of 29,300 shares, the short-interest ratio is currently 1.2 days.

Surrozen Price Performance

Shares of SRZN stock traded up $0.14 on Friday, hitting $9.85. The stock had a trading volume of 24,834 shares, compared to its average volume of 17,884. The company’s 50 day moving average price is $10.29 and its 200-day moving average price is $9.74. Surrozen has a 1 year low of $6.00 and a 1 year high of $16.19.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($2.77) by $2.33. The business had revenue of $10.00 million during the quarter. On average, sell-side analysts anticipate that Surrozen will post -7.16 EPS for the current year.

Hedge Funds Weigh In On Surrozen

Several hedge funds have recently added to or reduced their stakes in SRZN. Armistice Capital LLC purchased a new stake in Surrozen during the 2nd quarter valued at approximately $2,080,000. Nantahala Capital Management LLC purchased a new stake in shares of Surrozen during the second quarter worth approximately $2,050,000. Stonepine Capital Management LLC lifted its holdings in shares of Surrozen by 66.5% during the third quarter. Stonepine Capital Management LLC now owns 110,000 shares of the company’s stock worth $1,318,000 after purchasing an additional 43,916 shares during the period. Finally, CVI Holdings LLC purchased a new position in Surrozen in the 2nd quarter valued at $711,000. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.